Pfizer Limited (NSE:PFIZER)
India · Delayed Price · Currency is INR | Market Cap | 235.88B |
| Revenue (ttm) | 23.22B |
| Net Income (ttm) | 8.09B |
| Shares Out | 45.75M |
| EPS (ttm) | 176.76 |
| PE Ratio | 29.17 |
| Forward PE | 31.57 |
| Dividend | 35.00 (0.68%) |
| Ex-Dividend Date | Jul 9, 2025 |
| Volume | 20,956 |
| Average Volume | 65,450 |
| Open | 5,168.00 |
| Previous Close | 5,168.00 |
| Day's Range | 5,105.50 - 5,215.50 |
| 52-Week Range | 3,701.00 - 6,451.15 |
| Beta | 0.13 |
| RSI | 41.46 |
| Earnings Date | Aug 14, 2025 |
About Pfizer
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a netwo... [Read more]
Financial Performance
In 2024, Pfizer's revenue was 22.81 billion, an increase of 4.02% compared to the previous year's 21.93 billion. Earnings were 7.68 billion, an increase of 39.23%.
Financial StatementsNews
Pfizer shares jump over 5% as Q1 net profit surges 27.2% YoY
Pfizer Ltd’s shares surged 5.4% to ₹5,385 in early trade on Thursday after the pharmaceutical company reported robust first-quarter results for FY26. The company’s net profit grew 27.2% year-on-year (...
Pfizer shares jump over 2% after launch of next-gen 20-valent pneumococcal vaccine in India
Shares of Pfizer Limited rose 2.07% to Rs 5,165.50 on Tuesday, August 12, following the company’s announcement of the launch of its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vacc...